Drug Type Fc fusion protein |
Synonyms CD86 x NKG2a (Shattuck Labs), CD86-Fc-NKG2a |
Target |
Action agonists, antagonists |
Mechanism CD28 agonists(T-cell-specific surface glycoprotein CD28 agonists), NKG2A antagonists(killer cell lectin like receptor C1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Discovery | United States | 01 Nov 2019 |






